Sinclair Pharma receives EU approval for dry eye, oral health, dermatitis products

By Lisa Kerner

Charlotte, N.C., July 12 - Sinclair Pharma plc said it received E.U. regulatory approval for SPHP700 for dry eye, Decapinol Rinse for oral health and Atopiclair Fluid for dermatitis.

Sinclair believes Decapinol is the first new product class to enter the gingivitis market for several decades.

Atopiclair Fluid complements Atopiclair cream for relieving the signs and symptoms of eczema and irritant contact dermatitis.

The company said it will commercialize its products through marketing partners and plans to begin licensing discussions in the second half of this year.

"We are pleased to have achieved our first approval in the area of ophthalmology, a therapeutic area that is important to us in the future," chief executive Michael Flynn said in a company news release.

"We believe that SPHP700 is well-differentiated from existing prescription dry eye products and are confident that it will be an important product for the company."

Sinclair is a Godalming U.K.-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.